TTC9C Inhibitors
TTC9C inhibitors encompass a diverse range of compounds that interfere with various cellular signaling pathways, indirectly influencing the activity of TTC9C. For instance, mTOR inhibitors like rapamycin act on a major signaling pathway that regulates protein synthesis and cell growth, which are processes TTC9C may be involved in. By inhibiting mTOR, protein synthesis is downregulated, which could indirectly lead to decreased functional activity of TTC9C. Similarly, PI3K inhibitors such as LY294002 and wortmannin disrupt the PI3K/Akt pathway, a crucial signaling cascade for cell survival and growth. The suppression of this pathway can influence the role TTC9C plays in these processes, leading to its functional inhibition.
Other TTC9C inhibitors target kinases involved in cell cycle control and stress responses. CDK4/6 inhibitors like palbociclib halt the cell cycle in the G1 phase, which could affect TTC9C if it is associated with cell cycle regulation. The inhibition of MAPK pathways by compounds like PD98059 and U0126 can lead to the inactivation of proteins that interact with TTC9C, resulting in its functional inhibition. JNK inhibitors such as SP600125 affectapoptosis and inflammation pathways, potentially decreasing TTC9C activity if it is linked to these responses. Furthermore, Src family kinase inhibitors, like PP2 and dasatinib, block critical signaling involved in cell migration and proliferation, which could also impact TTC9C's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that impedes the mTOR pathway. Since TTC9C is associated with cellular growth and metabolism, the inhibition of mTOR can reduce protein synthesis and cellular proliferation, which could indirectly lead to decreased functional activity of TTC9C. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. By inhibiting various kinases, it can disrupt phosphorylation processes essential for the activation of numerous proteins, potentially including TTC9C if its function is phosphorylation-dependent. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that hinders the PI3K/Akt pathway. Since the PI3K/Akt pathway is involved in cell survival and growth signals which may impact TTC9C activity, inhibiting this pathway can indirectly reduce TTC9C's function in these processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that impedes the MAPK/ERK pathway. As the MAPK/ERK pathway is involved in cell division and differentiation, inhibiting this pathway can indirectly diminish the functional activity of TTC9C if it is implicated in these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts similarly to LY294002. It leads to inhibition of the PI3K/Akt pathway, resulting in potential downregulation of TTC9C's activity if it is involved in the survival and growth signals mediated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also an inhibitor of MEK, working similarly to PD98059, and thus affects the MAPK/ERK pathway. It can prevent the activation of downstream proteins that TTC9C might interact with, thereby indirectly inhibiting TTC9C's function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which suppresses the p38 MAPK stress-activated pathway. This pathway's inhibition could lead to the downregulation of proteins involved in stress response which may include TTC9C. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that blocks the JNK signaling pathway. This pathway is associated with apoptosis and inflammation. Inhibition here could result in the indirect reduction of TTC9C activity if TTC9C is involved in these cellular responses. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor that can suppress various cellular processes including cell migration and proliferation. By inhibiting these kinases, PP2 can indirectly inhibit TTC9C's function if it plays a role in these processes. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Bcr-Abl and Src family kinase inhibitor. By blocking these kinases, it can inhibit downstream signaling that may involve TTC9C, thus potentially reducing TTC9C's functional activity. | ||||||